Cargando…

Therapeutic Monoclonal Antibodies and Emergence of Their Biosimilars

Detalles Bibliográficos
Autor principal:	Jeddi-Tehrani, Mahmood
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Avicenna Research Institute 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960060/ https://www.ncbi.nlm.nih.gov/pubmed/29849980

Ejemplares similares

Biosimilar, biobetter and next generation therapeutic antibodies
Publicado: (2011)

Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies
por: Doevendans, Erik, et al.
Publicado: (2019)

The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
por: Barbier, Liese, et al.
Publicado: (2019)

Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies
por: Moorkens, Evelien, et al.
Publicado: (2016)

Expert perspectives on biosimilar monoclonal antibodies in breast cancer
por: Cortés, J., et al.
Publicado: (2014)

Biosimilar monoclonal antibodies in China: A patent review
por: Liu, Jia-Wei, et al.
Publicado: (2022)

An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
por: Moorkens, Evelien, et al.
Publicado: (2020)

EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies
por: Francescon, Sara, et al.
Publicado: (2018)

Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence
por: Jacobs, Ira, et al.
Publicado: (2016)

Production of Monoclonal Antibody against Human Nestin
por: Hadavi, Reza, et al.
Publicado: (2010)

Production and Characterization of a Murine Monoclonal Antibody Against Human Ferritin
por: Bayat, Ali Ahmad, et al.
Publicado: (2013)

Biosimilars
por: Martin, Miguel
Publicado: (2018)

Emerging Insights into European Markets of Biologics, Including Biosimilars
por: Simoens, Steven, et al.
Publicado: (2022)

Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challenges
por: Chapman, Kathryn, et al.
Publicado: (2016)

Biosimilar structural comparability assessment by NMR: from small proteins to monoclonal antibodies
por: Japelj, Boštjan, et al.
Publicado: (2016)

Characterization of Monoclonal and Polyclonal Antibodies Recognizing Prostate Specific Antigen: Implication for Design of a Sandwich ELISA
por: Raoofi Mohseni, Sahar, et al.
Publicado: (2019)

From Biologics to Biosimilars and Biobetters – Democratization of High-end Therapeutics
por: Honavar, Santosh G
Publicado: (2021)

Production and Characterization of Monoclonal Antibodies against Human Prostate Specific Antigen
por: Bayat, Ali Ahmad, et al.
Publicado: (2015)

Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective
por: Kurki, Pekka, et al.
Publicado: (2021)

Temperature Upshifts in Mammalian Cell Culture: A Suitable Strategy for Biosimilar Monoclonal Antibodies?
por: Marschall, Lukas, et al.
Publicado: (2023)

Development of Therapeutic Monoclonal Antibodies for Emerging Arbovirus Infections
por: Ormundo, Leonardo F., et al.
Publicado: (2023)

Approval of the first biosimilar antibodies in Europe: A major landmark for the biopharmaceutical industry
por: Beck, Alain, et al.
Publicado: (2013)

A rapid method for relative quantification of N-glycans from a therapeutic monoclonal antibody during trastuzumab biosimilar development
por: Segu, Zaneer, et al.
Publicado: (2020)

Differential Effects of Inhibitory and Stimulatory Anti-HER2 Monoclonal Antibodies on AKT/ERK Signaling Pathways
por: Soltantoyeh, Tahereh, et al.
Publicado: (2018)

Biosimilar insulin concepts
por: Bloomgarden, Zachary T.
Publicado: (2022)

Inhibition of the Receptor Tyrosine Kinase ROR1 by Anti-ROR1 Monoclonal Antibodies and siRNA Induced Apoptosis of Melanoma Cells
por: Hojjat-Farsangi, Mohammad, et al.
Publicado: (2013)

Special Issue: Monoclonal Antibodies
por: Klein, Christian
Publicado: (2018)

Conjugation of Monoclonal Antibodies to Super Paramagnetic Iron Oxide Nanoparticles for Detection of her2/neu Antigen on Breast Cancer Cell Lines
por: Shamsipour, Fereshteh, et al.
Publicado: (2009)

In silico design, construction and cloning of Trastuzumab humanized monoclonal antibody: A possible biosimilar for Herceptin
por: Akbarzadeh-Sharbaf, Soudabeh, et al.
Publicado: (2012)

Use of population approach non-linear mixed effects models in the evaluation of biosimilarity of monoclonal antibodies
por: Reijers, Joannes A. A., et al.
Publicado: (2016)

Human monoclonal antibodies as candidate therapeutics against emerging viruses
por: Jin, Yujia, et al.
Publicado: (2017)

The Development Pathway for Biosimilar Biotherapeutics
por: Zarbin, Marco
Publicado: (2020)

Here to Stay: Biosimilars in Hematology
por: Gribben, John, et al.
Publicado: (2019)

Journey of a therapeutic poison: Botulinum toxin A and its biosimilars
por: Bhattacharjee, Kasturi, et al.
Publicado: (2021)

Epitope Mapping of Human HER2 Specific Mouse Monoclonal Antibodies Using Recombinant Extracellular Subdomains
por: Ghatar, Reza Hosseini, et al.
Publicado: (2017)

Therapeutic Targets of Monoclonal Antibodies Used in the Treatment of Cancer: Current and Emerging
por: Effer, Brian, et al.
Publicado: (2023)

Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars
por: Uifălean, Alina, et al.
Publicado: (2018)

Therapeutic monoclonal antibody for sporotrichosis
por: Almeida, Sandro R.
Publicado: (2012)

Therapeutic Applications of Monoclonal Antibodies
por: Berger, Mitchell, et al.
Publicado: (2002)

Monoclonal Antibodies as Neurological Therapeutics
por: Gklinos, Panagiotis, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c3ft325v3s981p00filu77l72s